1 / 2

Survie sans progression et survie globale

Survie sans progression et survie globale. Survie sans progression. Survie globale (population en ITT). 1. 1. 0,8. 0,8. HR = 0,60 (IC 95 : 0,49-0,73) p < 0,00001. HR = 0,79 (IC 95 : 0,65-0,95) p = 0,012. 0,6. 0,6. Survie. Survie sans progression. 0,4. 0,4. 13,4 mois. 4,0 mois.

hien
Download Presentation

Survie sans progression et survie globale

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Survie sans progression et survie globale Survie sans progression Survie globale (population en ITT) 1 1 0,8 0,8 HR = 0,60 (IC95 : 0,49-0,73) p < 0,00001 HR = 0,79 (IC95 : 0,65-0,95) p = 0,012 0,6 0,6 Survie Survie sans progression 0,4 0,4 13,4 mois 4,0 mois 0,2 0,2 10,6 mois 2,0 mois 0 0 0 3 6 9 12 15 18 21 24 0 6 12 18 24 30 36 42 48 Mois Mois Placebo Pemetrexed ASCO 2009 - D’après Belani CP et al., abstract 8000 actualisé

  2. Survie globale en fonction de l’histologie Non épidermoïdes (n = 481) Épidermoïdes (n = 481) 1 1 HR = 0,70 (IC95 : 0,56-0,88) p = 0,002 HR = 1,07 (IC95 : 0,49-0,73) p = 0,678 0,8 0,8 0,6 0,6 Survie Survie 9,9 mois 15,5 mois 0,4 0,4 10,3 mois 0,2 0,2 10,8 mois 0 0 0 6 12 18 24 30 36 42 48 0 6 12 18 24 30 36 42 48 Mois Mois Placebo Pemetrexed ASCO 2009 - D’après Belani CP et al., abstract 8000 actualisé

More Related